Could Acinetobacter pittii act as an NDM-1 reservoir for enterobacteriaceae?

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2414-2415

  Bogaert, Pierre ^a   Huang, Te Din ^a   Castro, Roberta Rezende De ^a   Bouchahrouf, Warda ^a   Glupczynski, Youri ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Carbapenemases; Non fermenters; Plasmids; Type IV secretion systems

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEMASE; CIPROFLOXACIN; COLISTIN; DIPICOLINIC ACID; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; NEW DELHI METALLO BETA LACTAMASE 1; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER PITTII; ALCOHOLIC PANCREATITIS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ENTEROBACTERIACEAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION;

CARBAPENEMASES; NON-FERMENTERS; PLASMIDS; TYPE IV SECRETION SYSTEMS;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; DNA TRANSPOSABLE ELEMENTS; ENTEROBACTERIACEAE; GENE ORDER; GENE TRANSFER, HORIZONTAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84888780142     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt201     Document Type: Article

References (10)

1. Nordmann P, Poirel L, Walsh TR et al. The emerging NDM carbapenemases, Trends Microbiol, 2011; 19, 588-95.
2. Fu Y, Du X, Ji J et al. Epidemiological characteristics and genetic structure of blaNDM-1 in non-baumannii Acinetobacter spp, in China. J Antimicrob Chemother, 2012; 67, 2114-22.
3. Zong Z, Zhang X. blaNDM-1-carrying Acinetobacter johnsonii detected in hospital sewage, J Antimicrob Chemother, 2013; 68, 1007-10.
4. Wang Y, Wu C, Zhang Q et al. Identification of New Delhi metallo-blactamase-1 in Acinetobacter lwoffii of food animal origin. PLoS One 2012; 7: e37152.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI,Wayne, PA, USA, 2013.
6. Bogaerts P, Rezende De Castro R, De Mendonça R et al. Validation of carbapenemase and extended-spectrum b-lactamase multiplex endpoint PCR assays according to ISO 15189, J Antimicrob Chemother, 2013; 68, 1576-82.
7. Bogaerts P, Rezende De Castro R, Roisin S et al. Emergence of NDM-1-producing Acinetobacter baumannii in Belgium, J Antimicrob Chemother, 2012; 67, 1552-3.
8. Toleman MA, Spencer J, Jones L et al. blaNDM-1 is a chimera likely constructed in Acinetobacter baumannii, Antimicrob Agents Chemother, 2012; 56, 2773-6.
9. Hu H, Hu Y, Pan Y et al. Novel plasmid and its variant harboring both a blaNDM-1 gene and type IV secretion system in clinical isolates of Acinetobacter lwoffii. AntimicrobAgentsChemother 2012; 56: 1698-702.
10. Juhas M, Crook DW, Hood D.W. Type IV secretionsystems: tools ofbacterial horizontal gene transfer and virulence. Cell Microbiol 2008; 10: 2377-86.